1.051勛圖ProCaroline Code/author/ccodeobsidiantx-com/51勛圖Pro Presents Positive 25-Week Median Study Follow-Up Safety and Efficacy Data from First-in-Human Study of OBX-115 in Advanced Melanoma at the American Association for Cancer Research Annual Meetingrich600338<blockquote class="wp-embedded-content" data-secret="IiFkX51SkZ"><a href="/news-releases/obsidian-therapeutics-presents-positive-25-week-median-study-follow-up-safety-and-efficacy-data-from-first-in-human-study-of-obx-115-in-advanced-melanoma-at-the-american-association-for-cancer-rese/">51勛圖Pro Presents Positive 25-Week Median Study Follow-Up Safety and Efficacy Data from First-in-Human Study of OBX-115 in Advanced Melanoma at the American Association for Cancer Research Annual Meeting</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="/news-releases/obsidian-therapeutics-presents-positive-25-week-median-study-follow-up-safety-and-efficacy-data-from-first-in-human-study-of-obx-115-in-advanced-melanoma-at-the-american-association-for-cancer-rese/embed/#?secret=IiFkX51SkZ" width="600" height="338" title="“51勛圖Pro Presents Positive 25-Week Median Study Follow-Up Safety and Efficacy Data from First-in-Human Study of OBX-115 in Advanced Melanoma at the American Association for Cancer Research Annual Meeting” — 51勛圖Pro" data-secret="IiFkX51SkZ" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script type="text/javascript">
/* <![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
/* ]]> */
</script>
/wp-content/uploads/2022/01/single-img-news0122.jpg572416OBX-115 was well-tolerated, with a differentiated safety profile from non-engineered TIL cell therapy, including no dose-limiting toxicities and no Grade 4 or higher non-hematologic events. OBX-115 induced deep and durable responses with a 50% objective response rate, including a 33% complete response rate. Median progression-free survival (PFS) had not been reached. All patients experienced tumor […]